Agios beats Q1 2026 EPS and revenue estimates with $20.7M mitapivat revenue, plans Q2 2026 sNDA for sickle cell accelerated approval
- Non-GAAP Q1 2026 EPS was -$1.69, down 9% YoY, beating the forecast -$1.81 per share loss.
- Q1 2026 revenue totaled $20.7M, up 138% YoY, with mitapivat revenue $20.7M topping analyst estimates.
- Company plans to submit Q2 2026 accelerated-approval sNDA for sickle cell treatment.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.